EIFFL vs INDOUS: Stock Comparison

EIFFL vs INDO US BIOTECHUpdated 22 Jun 26, 4:08 PM ISTNSE & company filings

EIFFL is the larger company by market capitalisation. EIFFL shows faster revenue growth, while INDO US BIOTECH shows a lower P/E, a higher ROE and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

EIFFL leads 2; INDOUS leads 10 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

EIFFLINDOUS

Valuation lens

What price are you paying?

Market CapContext only
₹683 Cr
₹160 Cr
P/E RatioINDOUS has the lower reading
126.7x
0x
P/B RatioINDOUS has the lower reading
8.4x
0x
EPSINDOUS has the higher reading
₹0.3
₹1.51
Book ValueContext only
₹31.07
₹46.15
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
EIFFL is the larger company
₹683 Cr vs ₹160 Cr
P/E Ratio
INDOUS has a lower P/E
0x vs 126.7x
P/B Ratio
INDOUS has a lower P/B
0x vs 8.4x
EPS
INDOUS has higher earnings per share
₹1.51 vs ₹0.3
Revenue Growth (TTM YoY)
EIFFL has faster revenue growth
71.6% vs -22%
EPS Growth (TTM YoY)
EIFFL has faster EPS growth
80.5% vs -47.3%
Qtr Sales Growth
INDOUS has stronger quarterly sales growth
26.75% vs -39.92%
Qtr Profit Growth
INDOUS has stronger quarterly profit growth
54.05% vs -84.09%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricEIFFLINDOUS
SectorFast Moving Consumer GoodsFast Moving Consumer Goods
IndustryPackaged FoodsOther Agricultural Products

Price

MetricEIFFLINDOUS
Live Price₹356.54₹78.29
Day Change2.68%0.06%
Volume1.79 L2,095
52-Week High₹381.96₹159
52-Week Low₹204.98₹70
Distance from 52W High-6.66%-50.76%

Valuation

MetricEIFFLINDOUS
Market Cap₹683 Cr₹160 Cr
P/E Ratio126.7x0x
P/B Ratio8.4x0x
EPS₹0.3₹1.51
Book Value₹31.07₹46.15
Dividend Yield0%0%

Growth

MetricEIFFLINDOUS
Revenue Growth (TTM YoY)71.6%-22%
EPS Growth (TTM YoY)80.5%-47.3%
Qtr Sales Growth-39.92%26.75%
Qtr Profit Growth-84.09%54.05%

Profitability & Leverage

MetricEIFFLINDOUS
ROE6.11%14.18%
ROCE6.38%12.34%
Net Margin3.27%11.88%
Operating Margin8.21%14.64%
Debt to Equity0.62x0.4x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricEIFFLINDOUS
Promoter Holding73.5%68.29%
FII Holding0% 0.05 pp0.01% 0.17 pp
DII Holding2.06% 0.03 pp
Public Holding24.44% 0.02 pp31.7% 0.17 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: EIFFL and INDO US BIOTECH.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.